There is still no consensus on the value of Manchester Acute Coronary Syndromes (MACS) decision rule in detecting acute coronary syndrome (ACS). Therefore, the purpose of the present systematic review and meta-analyzes is to summarize the clinical evidence in the evaluation of the value of MACS in the diagnosis of ACS. Methods: A literature search was performed on the Medline, Embase, Scopus, and Web of Science databases. Outcomes included acute myocardial infarction (AMI) and major adverse cardiac event (MACE). Data were analyzed in the STATA 14.0 statistical program and the results were reported as summary receiver operating characteristics (SROC), sensitivity, specificity, positive and negative likelihood ratio, and diagnostic odds ratio with 95% confidence interval (95% CI). 
Introduction
A cute coronary syndrome (ACS) is a leading cause of mortality and disability worldwide. According to the statistics, in 2017, about 18 million deaths from cardiovascular disease have occurred in the world, which has increased by 21.1% over the past 10 years (1). This increase in the burden of cardiovascular disease has led researchers to seek solutions to reduce the incidence of ACS. Early diagnosis of ACS is one of the most effective methods to reduce the burden of the disease (2) . Currently, the patient' clinical examination, electrocardiography and serial troponin are the standard ACS diagnostic method. A golden standard for diagnosing ACS in emergency episodes is the serial troponin test (3) . However, the long-term approach to diagnosing ACS (about 6-12 hours) is the most important weakness of the current guidelines. In order to overcome this problem, Body et al in 2014 provided the Manchester Acute Coronary Syndromes (MACS) decision rule to the diagnosis of ACS (4) . In subsequent studies, the diagnostic value of this model was validated and modifications were made (5-9) (Table 1). In recent years, troponin-only MACS and history and electrocardiogram only MACS (HE-MACS) were introduced to overcome MACS shortcoming. However, there is still no comprehensive overview showing the performance of MACS and its modifications in rule out of ACS. Therefore, the purpose of the current systematic review and meta-analysis is to summarize the clinical evidence in assessing the value of MACS in the diagnosis of ACS.
Methods:

Search strategy
In the present meta-analysis using the keywords related to Manchester Acute Coronary Syndromes score in combination with Acute Coronary Syndrome, a search was performed in the Medline, Embase, Scopus, and Web of Science databases. The search was completed by the end of October 2018. No language restrictions were applied. The Searcy query for Medline (via PubMed) has been reported. 
Selection criteria
Inclusion criteria included relevant studies in the assessment of MACS in rule out of acute myocardial infarction (AMI) and major acute cardiac event (MACE). Exclusion criteria included the lack of the required data after contact with the authors, duplicate articles, and reviews.
Data synthases and quality control
The method of summarizing and collecting data has been reported by previous systematic reviews (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . In summary, two independent reviewers screened the titles and abstracts as well as full text of the articles and selected relevant studies. Any disagreement was resolved by discussion with the third reviewer. The collected data included the name of the first author, the year of study, the number of patients (normal, AMI, and MACE), the type of study (derivation and validation), the type of MACS (the original MACS, the troponin-only MACs, and HE-MACS), the assessed outcome (AMI and MACE) and follow-up duration. MACE included all-cause mortality, AMI, and urgent coronary revascularization. Quality assessment of the articles was evaluated using the proposed method of Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) guideline (26).
Statistical analysis
All analyzes were performed in the STATA 14.0 statistical program. Using the values reported in the relevant studies, we calculated true positive, true negative, false positive and false negative. Data were analyzed by "midas" command and the results were reported as a summary receiver operating characteristic (SROC) curve, sensitivity, specificity, positive and negative likelihood ratio, and diagnostic odds ratio with 95% confidence interval (95% CI). The publication bias was evaluated using Deeks' funnel plot asymmetry test. In all analyzes p <0.05 was considered a significant level.
Results:
Characteristics
The search led to the achievement of 3175 non-repetitive records. After the initial screening, 21 articles were studied in detail, and finally, eight papers arrived at the quantitative analysis (4-7, 9, 27-29). Figure 1 illustrates the flow diagram of the present meta-analysis. These eight articles contained 33 separate experiments. There were six cohort arti- cles and 2 of them were observational trials. Data from 7658 patients were analyzed. Of these, there were 1203 AMI and 1504 MACE. 64.29% of patients were male. Two studies were derivation-validation and other was validation. Table 2 provides a summary of related articles.
Quality control of articles and risk of bias
The quality assessment showed that the applicability of patient selection was high risk and unclear in two studies. In addition, in one study, the risk of bias in patient selection was unclear. In other cases, the risk of bias were low. Table  3 shows the quality status of the articles. Deeks funnel plot asymmetry test showed that there was no publication bias in the evaluation of the MACS in the rule out of AMI and MACE (Figure 2 ).
The value of MACS in rule out of AMI
Data from seven studies (15 separate experiments) included in this section. The analysis showed that the area under the SROC curve of MACS in the rule out of AMI was excellent (AUC = 0.99, 95% CI: 0.97 to 0.99) (Figure 3) . The sensitivity and specificity of the MACS decision aid in the diagnosis of AMI were 0.99 (95% CI: 0.98-0.99) and 0.24 (95% CI: 0.18-0.32), respectively. In addition, DOR of this rule out criteria was 29.0 (95% CI: 16.0-55.0) (Figure 4 and Table 4 ). The sensitivity and specificity of troponin-only MACS / HE-MACS in the diagnosis of AMI was 0.99 (95% CI: 0.98-0.99) and 0.22 (95% CI: 0.11-0.37), respectively. These values for the original (Table 4) .
Diagnostic value of MACS in MACE detection
Data from eight studies (18 separate experiments) were included in this section. The analysis showed that the area under the SROC curve of MACS in the rule out of MACE was excellent (AUC = 0.97, 95% CI: 0.95 to 0.98) (Figure 3) . The sensitivity, specificity and DOR of the MACS rule in prediction of MACE were 0.99 (95% CI: 0.98-0.99) and 0.25 (95% CI: 0.19-0.32), and 25.0 (95% CI: 13.0-43.0), respectively ( Figure 5 and Table 4 derivation studies (Table 4 ).
Discussion:
The findings of this study showed that the MACS value is good in the screening of AMI and MACE. It was also found that the value of troponin-only / HE-MACS is similar to the original MACS. Since troponin-only MACS and HE-MACS have fewer variables and don't need to evaluate the hearttype fatty acid binding protein, it seems that the use of troponin-only / HE-MACS is better than the original MACS. The MACS sensitivity to rule out of ACS is very high, but its specificity is low. Therefore, MACS is a good screening tool for AMI diagnosis and MACE prediction. In line with the present review article, Reynard et al. by reviewing five studiesconcluded that MACS is a good model for rule out of ACS (26) . In the present study, 8 articles included in the metaanalysis. Although data from 7658 patients were analyzed, 7 studies were conducted by a team in the UK (4-7, 9, 27, 28) . Only one study in Australia and New Zealand performed, that only 405 patients were examined (29) . Therefore, exter-nal validation of MACS in other communities is also required to ensure it is generalized. The findings of this study indicate that the performance of troponin-only MACS or HE-MACS in rule out of ACS is not different from the original MACS. One of the main disadvantages of the original MACS is the need to evaluate the hearttype fatty acid binding protein (h-FABP), while in the other two models, it is not necessary to measure h-FABP . The value of the troponin-only MACS in rule out of ACS was evaluated in four studies, while the value of HE-MACS was examined only in one study. Since the HE-MACS method does not require measurement of high sensitivity troponin and h-FABP, so if the screening value of HE-MACS is confirmed, it will be easier to use for rule out the ACS. Further studies are needed to achieve this goal.
Conclusion
The findings of this study showed that the original MACS, troponin-only MACS, and HE-MACS are capable to rule out AMI and MACE. However, further studies are needed in developing countries for external validation.
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